Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, ospemifene (Senshio®) cannot be endorsed for use within NHS Wales for the treatment of moderate to severe symptomatic vulvar and vaginal atrophy in post-menopausal women who are not candidates for local vaginal oestrogen therapy. This product is currently not marketed in the UK. |
||
|
||
Medicine details |
||
| Medicine name | ospemifene (Senshio™) | |
| Formulation | 60 mg film-coated tablet | |
| Reference number | 1960 | |
| Indication | For the treatment of moderate to severe symptomatic vulvar and vaginal atrophy in post-menopausal women who are not candidates for local vaginal oestrogen therapy. This product is currently not marketed in the UK. |
|
| Company | Shionogi Ltd | |
| BNF chapter | Endocrine system | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Ratification by Welsh Government | 15/05/2015 | |
| Date of issue | 20/05/2015 | |